TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35143617

Group type: EXPERIMENTAL
Intervention: Surgical revascularization
Number of subjects: 353

Group type: COMPARATOR
Intervention: Conservative arm of ISCHEMIA
Number of subjects: 353

Group type: COMPARATOR
Intervention: Revascularization arm of ISCHEMIA
Number of subjects: 353

Group type: COMPARATOR
Intervention: Invasive arm of ISCHEMIA
Number of subjects: 353
Study: 33819238

Group type: EXPERIMENTAL
Intervention: Structured exercise programme (5 weeks) including aerobics, stabilization, and pelvic floor muscle training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Postural education (Control)
Number of subjects: 16
Study: 36444391

Group type: EXPERIMENTAL
Intervention: CHECC‐uP intervention (cervical cancer brochure plus 30-60 min health literacy-focused education followed by monthly phone counselling and navigation assistance for 6 months)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (cervical cancer brochure)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: CHECC‐uP intervention
Number of subjects: 123
Study: 32440723

Group type: EXPERIMENTAL
Intervention: Drug-coated stent (DCS)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 278
Study: 32861197

Group type: EXPERIMENTAL
Intervention: Modified Mediterranean ketogenic diet (MMKD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: American Heart Association Diet (AHAD)
Number of subjects: 17
Study: 35032578

Group type: EXPERIMENTAL
Intervention: Stepped Care TF-CBT (SC-TF-CBT)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Standard TF-CBT
Number of subjects: 183
Study: 34029521

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU 4 times per day for 8 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 32826014

Group type: EXPERIMENTAL
Intervention: Kinesio-tape® (KT)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 7

Group type: COMPARATOR
Intervention: No tape (NT)
Number of subjects: 7
Study: 36058058

Group type: EXPERIMENTAL
Intervention: 1.5 kcal/ml enteral formula
Number of subjects: 80

Group type: COMPARATOR
Intervention: 1.0 kcal/ml enteral formula
Number of subjects: 80
Study: 34154344

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) combined with transcranial direct current stimulation (tDCS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional Chinese medicine (TCM)
Number of subjects: 60
Study: 34969649

Group type: EXPERIMENTAL
Intervention: Core muscle functional strength training (CMFST) for 12 weeks
Number of subjects: 588

Group type: COMPARATOR
Intervention: Control group (no extra training)
Number of subjects: 588
Study: 32020044

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy with lenalidomide (20 mg/day for days 1-21)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Standard chemotherapy without lenalidomide
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy with lenalidomide
Number of subjects: 222
Study: 36410482

Group type: EXPERIMENTAL
Intervention: Point of use (POU) arsenic filter with 3 calls promoting filter use (mHealth and filter only arm)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Point of use (POU) arsenic filter with 3 calls promoting filter use, 3 in-person home visits, and 3 Facebook messages (intensive arm)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Temporal variability in water arsenic concentrations
Number of subjects: 50
Study: 32100224

Group type: EXPERIMENTAL
Intervention: Dynamic combined training (12-week program, 3 days per week, including stretching, hydraulic resistance training, and cool-down)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Dynamic combined training
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 58
Study: 35168196

Group type: EXPERIMENTAL
Intervention: Exercise-based intervention 3 times per week for 16 weeks
Number of subjects: 424

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 424
Study: 34367647

Group type: EXPERIMENTAL
Intervention: Focus group and interview discussions regarding trial design
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Waiver of consent
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: General trial design discussions
Number of subjects: 17
Study: 35772219

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Continuous energy restriction (CER)
Number of subjects: 28
Study: 33752647

Group type: EXPERIMENTAL
Intervention: MUR service (intervention group)
Number of subjects: 153
Study: 32892376

Group type: EXPERIMENTAL
Intervention: Less invasive surfactant application (LISA)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Endotracheal intubation
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Less invasive surfactant application (LISA) in infants born at 25 and 26 weeks of GA
Number of subjects: 156

Group type: COMPARATOR
Intervention: Endotracheal intubation in infants born at 25 and 26 weeks of GA
Number of subjects: 156
Study: 33068348

Group type: EXPERIMENTAL
Intervention: Elongated needle group (needling depth 60‐73 mm)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Filiform needle group (needling depth 25‐30 mm)
Number of subjects: 70
Study: 35265334

Group type: EXPERIMENTAL
Intervention: Cesarean delivery on maternal request (CDMR)
Number of subjects: 6972
Study: 33596722

Group type: EXPERIMENTAL
Intervention: Cyproheptadine (8 mg, competitive 5-HT2 antagonist)
Number of subjects: 10
Study: 32215633

Group type: EXPERIMENTAL
Intervention: Mifepristone pretreatment plus misoprostol
Number of subjects: 300

Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 300
Study: 35422427

Group type: EXPERIMENTAL
Intervention: TD139 (0.3-10 mg once daily for 14 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: TD139 (0.15-50 mg single doses)
Number of subjects: 24
Study: 34599040

Group type: EXPERIMENTAL
Intervention: Octreotide acetate (low, medium, and high doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33516587

Group type: EXPERIMENTAL
Intervention: 2.0‐mm locking plating system
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2.0‐mm non-locking plating system
Number of subjects: 60
Study: 32114729

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF gel (10 mg per square centimeter, dressing change every 24 hours until complete healing)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF gel
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (aloe vera gel, same treatment protocol)
Number of subjects: 45
Study: 34240176

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 64
Study: 34089483

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 688

Group type: COMPARATOR
Intervention: Mechanical ventilation (MV)
Number of subjects: 688
Study: 34059974

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied before implant bed preparation and after suturing (808-nm GaAlA laser, 80 seconds; 11J/cm2)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no LLLT)
Number of subjects: 33
Study: 32162301

Group type: EXPERIMENTAL
Intervention: Mesorectal excision with lateral lymph node dissection (ME with LLND)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Mesorectal excision alone (ME alone)
Number of subjects: 701
Study: 33454232

Group type: EXPERIMENTAL
Intervention: Lavender essential oil inhalation (3 drops of 1.5% for 30 nights)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Chamomile essential oil inhalation (3 drops of 1.5% for 30 nights)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group (inhalation of distilled water for 30 nights)
Number of subjects: 183
Study: 34311063

Group type: EXPERIMENTAL
Intervention: lnLAEI (log-transformed left atrial expansion index)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: lnLAEI cutoff < 4.02
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Equation PCWP = 38.3 − 6.2 × lnLAEI
Number of subjects: 649
Study: 35230162

Group type: EXPERIMENTAL
Intervention: Bremelanotide 1.75 mg
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1202
Study: 36414783

Group type: EXPERIMENTAL
Intervention: One-shot cognitive behavioral therapy for insomnia (CBT-I)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 57
Study: 32606212

Group type: EXPERIMENTAL
Intervention: User-tested guidelines
Number of subjects: 273

Group type: COMPARATOR
Intervention: Current guidelines
Number of subjects: 273
Study: 32960536

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (AT; prophylactic antibiotics and steroids)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No treatment (AT-free group)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (AT)
Number of subjects: 43
Study: 36281094

Group type: EXPERIMENTAL
Intervention: Preoperative intravenous fluid loading with Ringer's lactate solution
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control (neither fluid nor ondansetron)
Number of subjects: 171
Study: 33638801

Group type: EXPERIMENTAL
Intervention: Evolocumab (140 mg subcutaneously injected once before revascularization + 14 days after the first dose)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Control group (no evolocumab injection)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 530

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 530
Study: 35615730

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound-guided biopsy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional ultrasound-guided biopsy
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound-guided biopsy (≥30 mm lesions)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional ultrasound-guided biopsy (≥30 mm lesions)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound-guided biopsy (<30 mm lesions)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional ultrasound-guided biopsy (<30 mm lesions)
Number of subjects: 110
Study: 33314799

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Mock laser acupuncture (ML)
Number of subjects: 76
Study: 32541773

Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO) 160 ppm plus oxygen/air for 30 min, five times/day, up to 5 days
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control: oxygen/air alone
Number of subjects: 69
Study: 34883305

Group type: EXPERIMENTAL
Intervention: Blueberry intake (26 g freeze-dried blueberries)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (26 g isocaloric matched placebo)
Number of subjects: 45
Study: 33682064

Group type: EXPERIMENTAL
Intervention: Theory of Mind (ToM) training conducted by nursing home operators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 32239237

Group type: EXPERIMENTAL
Intervention: Community-based screening for fracture risk
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Usual management
Number of subjects: 1000
Study: 35276667

Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 35275043

Group type: EXPERIMENTAL
Intervention: Hypercapnic hypoxia respiratory exercises (20 minutes per day, 14 to 16 sessions)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hypercapnic hypoxia respiratory exercises
Number of subjects: 42
Study: 32990454

Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy (DPT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study: 33580319

Group type: EXPERIMENTAL
Intervention: Indocyanine green fluorescence angiography (ICG‐FA) with PINPOINT®
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-perfusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diabetes
Number of subjects: 100
Study: 32311079

Group type: EXPERIMENTAL
Intervention: Repeated measures random forest (RMRF) algorithm
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: RMRF algorithm
Number of subjects: 127
Study: 32307669

Group type: EXPERIMENTAL
Intervention: One Anastomosis Gastric Bypass (OAGB)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 491
Study: 37170922

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg subcutaneously every 2 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 30
Study: 33316426

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy plus completion lymph node dissection (CLND)
Number of subjects: 2305

Group type: COMPARATOR
Intervention: Sentinel lymph node (SLN) biopsy without completion lymph node dissection (CLND)
Number of subjects: 2305

Group type: EXPERIMENTAL
Intervention: N2a disease
Number of subjects: 2305
Study: 32841904

Group type: EXPERIMENTAL
Intervention: Hyperarousal symptoms
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Reexperiencing and avoidance symptoms
Number of subjects: 247
Study: 35717166

Group type: EXPERIMENTAL
Intervention: MTV calculated using SUV4.0 threshold
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: TLG calculated using SUV4.0 threshold
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: MTV calculated using SUV140%L threshold
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: TLG calculated using SUV140%L threshold
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: MTV calculated using SUV41% threshold
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: TLG calculated using SUV41% threshold
Number of subjects: 107
Study: 34085953

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (plasma glucose < 3.0 mmol/L)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hypoglycemia
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Recovery from hypoglycemia
Number of subjects: 21
Study: 33777424

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Non-directive counselling
Number of subjects: 67
Study: 35351205

Group type: EXPERIMENTAL
Intervention: Individualised physiotherapy intervention
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Non-individualised intervention
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 91
Study: 33724883

Group type: EXPERIMENTAL
Intervention: 100 mg daily of canagliflozin
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 1900
Study: 34987499

Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells (PBMC) cultured and stimulated in vitro (n=68)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Plasma analysis for inflammatory markers (n=200)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Chalder Fatigue Questionnaire
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: PBMC cultures from CF+ group at 6 months
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Plasma analysis at 6 months
Number of subjects: 200
Study: 32003737

Group type: EXPERIMENTAL
Intervention: Intensive weight-loss program (IWLP)
Number of subjects: 42
Study: 35580621

Group type: EXPERIMENTAL
Intervention: Displaying cost and turnaround time (TAT) for reference laboratory tests at the time of order entry in the electronic health record (EHR) system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no display of cost and TAT)
Number of subjects: 0
Study: 34879449

Group type: EXPERIMENTAL
Intervention: Dupilumab (100 mg for those weighing ≤30 kg and 200 mg for those weighing >30 kg)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 408
Study: 33563642

Group type: EXPERIMENTAL
Intervention: Adjuvant vaginal cuff brachytherapy
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 182
Study: 32271036

Group type: EXPERIMENTAL
Intervention: Sampling techniques for characterizing behavior from audio recordings
Number of subjects: 11
Study: 35743988

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electric Nerve Stimulation (TENS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo-TENS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 80
Study: 34022791

Group type: EXPERIMENTAL
Intervention: Nomogram incorporating lactate level
Number of subjects: 1986

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 1986
Study: 33023946

Group type: EXPERIMENTAL
Intervention: Canakinumab treatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Baseline levels of CRP or IL6
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Other inflammatory markers outside of IL1β pathway
Number of subjects: 71
Study: 33951633

Group type: EXPERIMENTAL
Intervention: 1-week multimodal program for stress reduction (health coaching, relaxation, physical activity, balneotherapeutic elements)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 1-week multimodal program for stress reduction
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group B
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group C
Number of subjects: 96
Study: 33744300

Group type: EXPERIMENTAL
Intervention: Health-E You mobile health application
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Control group (iPads with sexual health questions)
Number of subjects: 1360
Study: 36049660

Group type: EXPERIMENTAL
Intervention: Upward comparison condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Downward comparison condition
Number of subjects: 0
Study: 34550072

Group type: EXPERIMENTAL
Intervention: VR-MRI app
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard Preparatory Manual (SPM)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Child Life Program (CLP)
Number of subjects: 84
Study: 33267925

Group type: EXPERIMENTAL
Intervention: AMPH EROS (7.5 mL of 2.5 mg/mL, equivalent to 18.8 mg of amphetamine base)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ER MAS (30 mg capsule, equivalent to 18.8 mg of amphetamine base)
Number of subjects: 30
Study: 32034912

Group type: EXPERIMENTAL
Intervention: Acoustic closed-loop stimulation during sleep
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham stimulation (placebo control)
Number of subjects: 29
Study: 33341413

Group type: EXPERIMENTAL
Intervention: DISCO intervention group (systematic follow‐up by a dietitian to adhere to the Dietary Approaches to Stop Hypertension nutrition model together with optimal medical therapy [OMT])
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (OMT alone)
Number of subjects: 92
Study: 33418231

Group type: EXPERIMENTAL
Intervention: Nomogram based on nutritional and inflammatory indicators for overall survival (OS) prediction
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Nomogram based on nutritional and inflammatory indicators for disease-free survival (DFS) prediction
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: High-risk group based on nomogram
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Surgery in high-risk group
Number of subjects: 93
Study: 32805740

Group type: EXPERIMENTAL
Intervention: n-3 LC-PUFAs (1 g of fish oil 3 times a day for 2 months containing 360 mg EPA and 240 mg DHA)
Number of subjects: 6
Study: 35085341

Group type: EXPERIMENTAL
Intervention: 3-month exercise and dietary lifestyle intervention (n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard-of-care management (n = 16)
Number of subjects: 32
Study: 34115731

Group type: EXPERIMENTAL
Intervention: Dance intervention (n = 20)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (n = 19)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Dance and exercise interventions
Number of subjects: 39

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 39
Study: 32707001

Group type: EXPERIMENTAL
Intervention: MRG-110 (0.01 to 1.5 mg/kg body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRG-110 (1.5 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35263681

Group type: EXPERIMENTAL
Intervention: holoBLG lozenge
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 51
Study: 33441157

Group type: EXPERIMENTAL
Intervention: Qing‐Chang‐Hua‐Shi granule (QCHS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 32745734

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d) plus Clopidogrel (75 mg/d) for 6 months followed by random assignment to aspirin plus clopidogrel for an additional 6 months
Number of subjects: 480

Group type: COMPARATOR
Intervention: Aspirin (100 mg/d) plus Placebo for an additional 6 months
Number of subjects: 480

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/d) plus Placebo for an additional 6 months
Number of subjects: 480
Study: 34755919

Group type: EXPERIMENTAL
Intervention: Adaptive computerised working memory training (WMT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-adaptive control working memory training (placebo)
Number of subjects: 72
Study: 34081322

Group type: EXPERIMENTAL
Intervention: Gleason 6 out of 10 prostate cancer
Number of subjects: 718

Group type: COMPARATOR
Intervention: Grade group 1 out of 5 prostate cancer
Number of subjects: 718

Group type: COMPARATOR
Intervention: Indolent lesion of epithelial origin
Number of subjects: 718
Study: 32708355

Group type: EXPERIMENTAL
Intervention: Principal component 1 (diabetes, heart disease, and hypertension)
Number of subjects: 10217

Group type: EXPERIMENTAL
Intervention: Principal component 3 (psychiatric and cerebrovascular diseases)
Number of subjects: 10217

Group type: EXPERIMENTAL
Intervention: Principal component 4
Number of subjects: 10217

Group type: EXPERIMENTAL
Intervention: Principal component 4 among participants aged 45-64 years
Number of subjects: 10217
Study: 35130348

Group type: EXPERIMENTAL
Intervention: Miniscrew-supported palatal crib (MSPC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional fixed palatal crib (CFPC)
Number of subjects: 26
Study: 33142016

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 576

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576